Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis.
The evaluation of the efficacy of an immunochemotherapy protocol to treat symptomatic dogs naturally infected with Leishmania chagasi was studied. This clinical trial had the purpose to test the combination of N-methyl meglumine antimoniate (Glucantime and the second generation recombinant vaccine Leish-110f plus the adjuvant MPL-SE to treat the canine leishmaniasis (CanL). Thirty symptomatic naturally infected mongrel dogs were divided into five groups. Animals received standard treatment with Glucantime or treatment with Glucantime Leish-110f + MPL-SEas immunochemotherapy protocol. Additional groups received Leish-110f + MPL-SE only, MPL-SE only, or placebo. Evaluation of haematological, biochemical (renal and hepatic function) and plasmatic proteins, immunological (humoral and cellular immune response) and the parasitological test revealed improvement of the clinical parameters and parasitological cure in dogs in both chemotherapy alone and immunochemotherapy cohorts. However, the immunotherapy and immunochemotherapy cohorts had reduced number of deaths, higher survival probability, and specific cellular reactivity to leishmanial antigens, in comparison with chemotherapy cohort only and control groups (adjuvant alone and placebo). These results support the notion of using well-characterized recombinant vaccine as an adjunct to improve the current chemotherapy of CanL.
Miret
Jorge
J
Laboratório de Leishmanioses e Vacinas, Departamento de Parasitologia, Instituto de Ciências Biológicas (ICB), Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
Nascimento
Evaldo
E
Sampaio
Weverton
W
França
João Carlos
JC
Fujiwara
Ricardo Toshio
RT
Vale
André
A
Dias
Edelberto Santos
ES
Vieira
Edvá
E
da Costa
Roberto Teodoro
RT
Mayrink
Wilson
W
Campos Neto
Antonio
A
Reed
Steven
S
D000818:Animals; D000913:Antibodies, Protozoan / Q000032:analysis / Q000096:biosynthesis; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D004283:Dog Diseases / Q000276:immunology* / Q000517:prevention & control; D004285:Dogs; D005260:Female; D005500:Follow-Up Studies; D007167:Immunotherapy; D018314:Leishmania infantum / Q000276:immunology*; D054332:Leishmaniasis Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D007898:Leishmaniasis, Visceral / Q000276:immunology* / Q000469:parasitology / Q000662:veterinary*; D008297:Male; D008536:Meglumine / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors; D015996:Survival Rate; D013601:T-Lymphocytes / Q000276:immunology; D014614:Vaccines, Synthetic / Q000627:therapeutic use
D000913:Antibodies, Protozoan; D000981:Antiprotozoal Agents; D054332:Leishmaniasis Vaccines; D009942:Organometallic Compounds; D014614:Vaccines, Synthetic; D008536:Meglumine; D000077485:Meglumine Antimoniate